Altace®
Ramipril is an ACE inhibitor for hypertension, heart failure, and cardiovascular risk reduction. Shown in HOPE trial to reduce MI, stroke, and CV death.
| Dosage Form | Oral Capsule |
| Strength | 1.25 mg, 2.5 mg, 5 mg, 10 mg |
| Storage | Store at 15–30°C. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Hypertension; heart failure post-MI; reduction of MI, stroke, and CV death in high-risk patients.
Prodrug converted to ramiprilat, which inhibits ACE, reducing conversion of angiotensin I to angiotensin II. Decreases aldosterone, reduces vasoconstriction, and increases bradykinin.
Each Burrard Pharmaceuticals technology transfer package for Ramipril includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.